Westchester Capital Management (New York)’s NRX Pharmaceuticals NRXP Stock Holding History

Westchester Capital Management (New York)’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-24,466	Closed	-$2.59M	–	169
2019 Q3	$2.59M	Hold	24,466	–	–	0.1%	96
2019 Q2	$2.56M	Sell	24,466 -10	-0%	-$1.04K	0.08%	88
2019 Q1	$2.54M	Hold	24,476	–	–	0.09%	85
2018 Q4	$2.5M	Hold	24,476	–	–	0.11%	81
2018 Q3	$2.45M	Hold	24,476	–	–	0.09%	78
2018 Q2	$2.42M	Hold	24,476	–	–	0.1%	62
2018 Q1	$2.4M	Buy	+24,476	New	+$2.39M	0.09%	63

Other funds holding NRXP

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

VOAM

Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return

Westchester Capital Management (New York)'s NRXP Position: Q4 2019 in Review

Westchester Capital Management (New York) sold out of NRX Pharmaceuticals (NRXP) in Q4 2019, closing a stake of 24,466 shares — an estimated $2.59M sold.

Westchester Capital Management (New York) first reported a position in NRXP in Q1 2018 and held it in 7 quarters. The position peaked at $2.59M in Q3 2019. 13 funds tracked by Wall St. Rank hold NRXP as of Q4 2019.

Westchester Capital Management (New York) reported no remaining NRX Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Westchester Capital Management (New York) sold 24,466 NRX Pharmaceuticals shares in Q4 2019, an estimated $2.59M.
Westchester Capital Management (New York) first reported a position in NRX Pharmaceuticals in Q1 2018 and held it in 7 quarters.
Westchester Capital Management (New York)'s NRX Pharmaceuticals position peaked at $2.59M in Q3 2019.
13 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q4 2019.

Based on Westchester Capital Management (New York)'s 13F filing for Q4 2019, filed 14 Feb 2020.